Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined With Radiation in Colorectal Cancer

Overview

Journal In Vivo

Specialty Oncology

Date 2020 Nov 4

PMID 33144426

Citations 5

Authors

Yu-Chang Liu

I-Tsang Chiang

Jing-Gung Chung

Jung-Hung Hsieh

Chih-Hung Chiang

Mao-Chi Weng

Fei-Ting Hsu

Yuan-Hao Lee

Cheng-Shyong Chang

Song-Shei Lin

Affiliations

Soon will be listed here.

Abstract

Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-κB) and compromise patients' survival. Regorafenib suppresses NF-κB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown.

Materials And Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining.

Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-κB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group.

Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT.

Citing Articles

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study.

Yan H, Liu J, Zhang Y, Chen S, Xu J, Gao D J Gastrointest Oncol. 2024; 15(3):987-1001.

PMID: 38989408 PMC: 11231874. DOI: 10.21037/jgo-24-180.

Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments.

Abedizadeh R, Majidi F, Khorasani H, Abedi H, Sabour D Cancer Metastasis Rev. 2023; 43(2):729-753.

PMID: 38112903 DOI: 10.1007/s10555-023-10158-3.

Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT).

Zhou S, Wang C, Shen L, Wang Y, Zhang H, Wu R Front Oncol. 2023; 13:1274487.

PMID: 37869085 PMC: 10586789. DOI: 10.3389/fonc.2023.1274487.

Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review.

Wang R, Cong D, Bai Y, Zhang W Front Pharmacol. 2023; 14:1207369.

PMID: 37448961 PMC: 10336539. DOI: 10.3389/fphar.2023.1207369.

Modulation of the Tumor Microenvironment by Microbiota-Derived Short-Chain Fatty Acids: Impact in Colorectal Cancer Therapy.

Gomes S, Rodrigues A, Pazienza V, Preto A Int J Mol Sci. 2023; 24(6).

PMID: 36982144 PMC: 10048801. DOI: 10.3390/ijms24065069.

References

Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A . The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression. Medicine (Baltimore). 2018; 96(48):e9023. PMC: 5728821. DOI: 10.1097/MD.0000000000009023. View

Li F, Sethi G . Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta. 2010; 1805(2):167-80. DOI: 10.1016/j.bbcan.2010.01.002. View

Noble P, Vyas M, Al-Attar A, Durrant S, Scholefield J, Durrant L . High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival. Br J Cancer. 2013; 108(10):2097-105. PMC: 3670501. DOI: 10.1038/bjc.2013.166. View

Krishnamoorthy S, Relias V, Sebastian S, Jayaraman V, Saif M . Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol. 2015; 8(5):285-97. PMC: 4530428. DOI: 10.1177/1756283X15580743. View

Liu H, Zhang L, Li G, Gao Z . Xanthohumol protects against Azoxymethane-induced colorectal cancer in Sprague-Dawley rats. Environ Toxicol. 2019; 35(2):136-144. DOI: 10.1002/tox.22849. View

Rahmanian N, Hosseinimehr S, Khalaj A . The paradox role of caspase cascade in ionizing radiation therapy. J Biomed Sci. 2016; 23(1):88. PMC: 5142153. DOI: 10.1186/s12929-016-0306-8. View

Kim J . Controversial issues in radiotherapy for rectal cancer: a systematic review. Radiat Oncol J. 2018; 35(4):295-305. PMC: 5769877. DOI: 10.3857/roj.2017.00395. View

Sandur S, Deorukhkar A, Pandey M, Pabon A, Shentu S, Guha S . Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys. 2009; 75(2):534-42. PMC: 3090721. DOI: 10.1016/j.ijrobp.2009.06.034. View

Weng M, Li M, Chung J, Liu Y, Wu J, Hsu F . Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo. Biomed Pharmacother. 2019; 116:109032. DOI: 10.1016/j.biopha.2019.109032. View

10.

Manente L, Pecoraro S, Picillo E, Gargiulo U, Gargiulo P, De Luca A . Molecular evidence of apoptotic pathway activation in semen samples with high DNA fragmentation. In Vivo. 2015; 29(2):289-94. View

11.

Chen Y, Sun R, Chen W, Yau Y, Hsu F, Chung J . The Radiosensitizing Effect of Magnolol on Tumor Growth of Hepatocellular Carcinoma. In Vivo. 2020; 34(4):1789-1796. PMC: 7439903. DOI: 10.21873/invivo.11973. View

12.

Kunnumakkara A, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal B . Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 2008; 14(7):2128-36. DOI: 10.1158/1078-0432.CCR-07-4722. View

13.

Jensen L, Olesen R, Petersen L, Boysen A, Andersen R, Lindebjerg J . Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. Cancers (Basel). 2019; 11(11). PMC: 6896074. DOI: 10.3390/cancers11111649. View

14.

Liu Y, Tsai J, Weng Y, Hsu F . Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer. Biomed Pharmacother. 2020; 128:110319. DOI: 10.1016/j.biopha.2020.110319. View

15.

Su C, Weng Y, Kuan L, Chen J, Hsu F . Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo. Int J Mol Sci. 2020; 21(10). PMC: 7278962. DOI: 10.3390/ijms21103527. View

16.

Tam S, Wu V . A Review on the Special Radiotherapy Techniques of Colorectal Cancer. Front Oncol. 2019; 9:208. PMC: 6454863. DOI: 10.3389/fonc.2019.00208. View

17.

Mercier J, Voutsadakis I . A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer. Anticancer Res. 2017; 37(11):5925-5934. DOI: 10.21873/anticanres.12039. View

18.

Celec P . Nuclear factor kappa B--molecular biomedicine: the next generation. Biomed Pharmacother. 2004; 58(6-7):365-71. DOI: 10.1016/j.biopha.2003.12.015. View

19.

Fiorino C, Guckemberger M, Schwarz M, van der Heide U, Heijmen B . Technology-driven research for radiotherapy innovation. Mol Oncol. 2020; 14(7):1500-1513. PMC: 7332218. DOI: 10.1002/1878-0261.12659. View

20.

Calvaruso M, Pucci G, Musso R, Bravata V, Cammarata F, Russo G . Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy. Int J Mol Sci. 2019; 20(21). PMC: 6861933. DOI: 10.3390/ijms20215267. View